# EQUULEUS (NCT01998971)

> A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma

No report yet. It can be ordered.

- Drugs tested: daratumumab plus carfilzomib plus dexamethasone; daratumumab plus pomalidomide plus dexamethasone; daratumumab plus carfilzomib plus lenalidomide plus dexamethasone
- Indication: multiple myeloma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01998971
- Phase: PHASE1
- Status: COMPLETED
- Sponsor: Janssen Research & Development, LLC
- Conditions: Multiple Myeloma
- Interventions: Daratumumab; Velcade; Pomalidomide; Dexamethasone; Melphalan; Prednisone; Thalidomide; Diphenhydramine; Acetaminophen; Carfilzomib; Lenalidomide; Montelukast
- Enrollment: 240
- Primary outcome: Number of participants affected by adverse events by MedDRA system organ class (SOC) and Preferred term (PT)
- Primary outcome: Number of participants affected by dose-limiting toxicities

## Indexed commentary on EQUULEUS so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 9 posts on X
- 4 YouTube videos

## Order

Standard, $1,250 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=equuleus-nct01998971

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT01998971", "email": "<work email>"}; the inbox owner confirms by the emailed link.